Ruxolitinib for the treatment of primary myelofibrosis
Author:
Affiliation:
1. Leukemia, Division of Pharmacy, University of Texas, M. D. Anderson Cancer Center, Houston
Publisher
Oxford University Press (OUP)
Subject
Health Policy,Pharmacology
Link
http://academic.oup.com/ajhp/article-pdf/71/6/453/28372308/ajhp0453.pdf
Reference31 articles.
1. Primary myelofibrosis: update on definition, pathogenesis, and treatment;Abdel-Wahab;Annu Rev Med,2009
2. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001–2004, using data from the NAACCR and SEER programs;Rollison;Blood,2008
3. Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients;Visani;Br J Haematol,1990
4. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment;Cervantes;Blood,2009
5. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment);Passamonti;Blood,2010
Cited by 14 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Socio-Demographic Determinants of Myelofibrosis Outcomes in an Underserved Center and the SEER National Database;2024-07-26
2. Socio-demographic determinants of myelofibrosis outcomes in an underserved center and the SEER national database;Annals of Hematology;2024-07-24
3. Primer consenso interinstitucional de neoplasias mieloproliferativas crónicas;Gaceta Médica de México;2023-09-20
4. Molecular modeling studies of fused pyrimidine derivatives at various receptors;Fused Pyrimidine-Based Drug Discovery;2023
5. 3-Deoxy-2β,16-dihydroxynagilactone E, a natural compound from Podocarpus nagi, preferentially inhibits JAK2/STAT3 signaling by allosterically interacting with the regulatory domain of JAK2 and induces apoptosis of cancer cells;Acta Pharmacologica Sinica;2019-06-14
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3